Julien Delrieu1, Pierre Payoux2, Isabelle Carrié3, Christelle Cantet4, Michael Weiner5, Bruno Vellas4, Sandrine Andrieu6. 1. INSERM UMR 1027, Toulouse, France; University of Toulouse III, Toulouse, France; Gérontopôle, Department of Geriatrics, Toulouse (University Hospital) CHU, Purpan University Hospital, Toulouse, France. Electronic address: delrieu.j@chu-toulouse.fr. 2. Department of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, France; Toulouse NeuroImaging Center, University of Toulouse, INSERM, UPS, Toulouse, France. 3. Gérontopôle, Department of Geriatrics, Toulouse CHU, Purpan University Hospital, Toulouse, France. 4. INSERM UMR 1027, Toulouse, France; University of Toulouse III, Toulouse, France; Gérontopôle, Department of Geriatrics, Toulouse (University Hospital) CHU, Purpan University Hospital, Toulouse, France. 5. Department of radiology and biomedical imaging University of California, San Francisco, San Francisco, CA, USA. 6. INSERM UMR 1027, Toulouse, France; University of Toulouse III, Toulouse, France; Department of Epidemiology and Public Health, Toulouse CHU, Toulouse, France.
Abstract
INTRODUCTION: The Multidomain Alzheimer Preventive Trial (MAPT) assessed the efficacy of omega-3 fatty acid supplementation, a multidomain intervention (MI), or a combination of both on cognition. Impact according to cerebral amyloid status was evaluated by PET scan. METHODS:Participants were nondemented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. The primary outcome was a change from baseline in 36 months measured with a cognitive composite Z score. RESULTS: No effect was observed on cognition in the negative amyloid group (n = 167). In the positive amyloid group (n = 102), we observed a difference of 0.708 and 0.471 in the cognitive composite score between the MI plus omega-3 fatty acid group, the MI alone group, and the placebo group, respectively. DISCUSSION: MI alone or in combination with omega-3 fatty acids was associated with improved primary cognitive outcome in subjects with positive amyloid status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01513252.
RCT Entities:
INTRODUCTION: The Multidomain Alzheimer Preventive Trial (MAPT) assessed the efficacy of omega-3 fatty acid supplementation, a multidomain intervention (MI), or a combination of both on cognition. Impact according to cerebral amyloid status was evaluated by PET scan. METHODS:Participants were nondemented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. The primary outcome was a change from baseline in 36 months measured with a cognitive composite Z score. RESULTS: No effect was observed on cognition in the negative amyloid group (n = 167). In the positive amyloid group (n = 102), we observed a difference of 0.708 and 0.471 in the cognitive composite score between the MI plus omega-3 fatty acid group, the MI alone group, and the placebo group, respectively. DISCUSSION: MI alone or in combination with omega-3 fatty acids was associated with improved primary cognitive outcome in subjects with positive amyloid status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01513252.
Authors: Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier Journal: Lancet Date: 2021-03-02 Impact factor: 79.321
Authors: Md Tanvir Kabir; Md Sahab Uddin; Philippe Jeandet; Talha Bin Emran; Saikat Mitra; Ghadeer M Albadrani; Amany A Sayed; Mohamed M Abdel-Daim; Jesus Simal-Gandara Journal: Mar Drugs Date: 2021-04-28 Impact factor: 5.118
Authors: Serge Gauthier; P S Aisen; J Cummings; M J Detke; F M Longo; R Raman; M Sabbagh; L Schneider; R Tanzi; P Tariot; M Weiner; J Touchon; B Vellas Journal: J Prev Alzheimers Dis Date: 2020-04-06
Authors: Jetske van der Schaar; Leonie N C Visser; Femke H Bouwman; Johannes C F Ket; Philip Scheltens; Annelien L Bredenoord; Wiesje M van der Flier Journal: Alzheimers Res Ther Date: 2022-02-10 Impact factor: 6.982
Authors: Guoqiao Wang; Lei Liu; Yan Li; Andrew J Aschenbrenner; Randall J Bateman; Paul Delmar; Lon S Schneider; Richard E Kennedy; Gary R Cutter; Chengjie Xiong Journal: Alzheimers Dement (N Y) Date: 2022-04-05